January 30, 2015 3:31 AM ET

Biotechnology

Company Overview of KaloBios Pharmaceuticals, Inc.

Company Overview

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. Its product candidates include KB001-A, which is in a Phase II clinical trial for the prevention and treatment of pseudomonas aeruginosa infection in mechanically ventilated and cystic fibrosis patients; KB003 that is in a Phase II clinical trial for the treatment of inflammatory diseases; and KB004, which is in a Phase I clinical trial for the treatment of hematologic malignancies and solid tumors. The company has a collaboration agreement with Sanofi Pasteur S.A. for the development of KB001-A. KaloBios P...

260 East Grand Avenue

South San Francisco, CA 94080

United States

Founded in 2000

31 Employees

Phone:

650-243-3100

Key Executives for KaloBios Pharmaceuticals, Inc.

Chief Medical Officer
Age: 56
Total Annual Compensation: $410.0K
Chief Scientific Officer
Age: 62
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.

KaloBios Pharmaceuticals, Inc. Key Developments

KaloBios Pharmaceuticals, Inc. Announces Management Changes

KaloBios Pharmaceuticals, Inc. announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's board of directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.

Kalobios Pharmaceuticals Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients

KaloBios Pharmaceuticals, Inc. announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms (an indicator of reduction of the risk to develop pulmonary exacerbations) was not met. The company also evaluated time to need for antibiotics in a number of pre-specified subgroup analyses known to be associated with such risk and none demonstrated an improvement for KB001-A versus placebo. In addition, secondary endpoints such as improvements in FEV1 and subject-reported outcomes as measured by Cystic Fibrosis Respiratory Symptom Diary (CFRSD) did not show an advantage with KB001-A treatment. The Phase 2 clinical study of KB001-A in CF subjects with Pa lung infections was a randomized, double-blind, placebo controlled study in which 182 subjects were randomized one to one between treatment with KB001-A or placebo. Eligible subjects were identified as CF patients whose lungs were colonized with Pa at the time of entry into the study, and who had been compliant in taking their antibiotics for at least the preceding two cycles. Subjects enrolled in the 16 week study were allowed to continue on their antibiotics in the first four weeks of the study, after which antibiotics were withdrawn for the remainder of their time on the study. Throughout the 16 week study duration, subjects received either placebo or KB001-A dosed at 10 mg/kg every four weeks via intravenous administration with one additional loading dose at Week 2. The primary endpoint of the study was the time to need for antibiotics for respiratory signs and symptoms and was analytically expressed as a hazard ratio.

KaloBios Pharmaceuticals, Inc. - Special Call

To provide an overview of the trial results of Phase 2 study of KB001-A

Similar Private Companies By Industry

Company Name Region
Genetic Medisyn Corp. United States
Symphony Dynamo, Inc. United States
Saigene Corporation United States
Bimini Technologies LLC United States
Enzybiotics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KaloBios Pharmaceuticals, Inc., please visit www.kalobios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.